{"id":"NCT02897349","sponsor":"Boehringer Ingelheim","briefTitle":"Linagliptin Add-on to Insulin Background Therapy","officialTitle":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin, Administered Orally Once Daily, in Combination With Insulin Therapy for 24 Weeks in Chinese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-30","primaryCompletion":"2019-01-11","completion":"2019-01-18","firstPosted":"2016-09-13","resultsPosted":"2020-01-21","lastUpdate":"2020-03-25"},"enrollment":206,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"linagliptin","otherNames":[]},{"type":"DRUG","name":"background therapy","otherNames":[]}],"arms":[{"label":"linagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control","primaryOutcome":{"measure":"Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Placebo Matching Linagliptin","deltaMin":-0.2,"sd":0.09},{"arm":"Linagliptin","deltaMin":-0.61,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":25,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":102},"commonTop":["Hypoglycaemia","Upper respiratory tract infection","Hyperuricaemia"]}}